Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. MYLAN INC. (D.N.J. 2014)

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. MYLAN INC. (D.N.J. 2014)

Docket		Date Filed	2014-07-11
Court	District Court, D. New Jersey	Date Terminated	2018-03-05
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Patents	8,017,615; 8,580,796; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. MYLAN INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-11				External link to document

Otsuka Pharmaceutical v. Mylan Inc. Litigation Summary, Case No. 1:14-cv-04508

Last updated: September 25, 2026

Otsuka Pharmaceutical Co., Ltd. sued Mylan Inc. in the U.S. District Court for the District of New Jersey after Mylan filed an abbreviated new drug application seeking approval for generic aripiprazole, the active ingredient in Otsuka’s Abilify products. The action was an ANDA patent case under the Hatch-Waxman Act. The case ended without a reported merits decision, and no publicly reported judgment invalidated or held enforceable the asserted Otsuka patents in this action.

What drug and patents were involved in Otsuka v. Mylan?

The dispute concerned generic aripiprazole tablets, the active ingredient in Abilify. Otsuka marketed Abilify for schizophrenia, bipolar disorder, major depressive disorder adjunctive treatment and related indications.

The case is generally associated with Otsuka’s later-generation aripiprazole patent estate rather than the original compound patent litigated in earlier Abilify cases.

Item	Details
Plaintiff	Otsuka Pharmaceutical Co., Ltd.
Defendant	Mylan Inc.
Court	U.S. District Court for the District of New Jersey
Case number	1:14-cv-04508
Technology	Oral aripiprazole tablets
Regulatory pathway	Abbreviated New Drug Application
Brand product	Abilify
Active ingredient	Aripiprazole
Litigation type	Hatch-Waxman patent infringement
Reported merits ruling	None identified
Disposition	Resolved and terminated without a reported trial judgment

The asserted patent set included U.S. Patent No. 8,017,615, which Otsuka listed for aripiprazole products and which was directed to pharmaceutical compositions containing aripiprazole. Public case summaries and patent records should be read together because Orange Book listings, product strengths and asserted claims can differ across related Abilify cases.

What was the legal basis for the lawsuit?

Otsuka filed the action under 35 U.S.C. § 271(e)(2), which treats the submission of an ANDA containing a Paragraph IV certification as an act of patent infringement for purposes of determining whether FDA approval should be delayed.

Mylan’s ANDA certification challenged at least one listed Otsuka patent. Otsuka responded by alleging that commercial manufacture, use or sale of Mylan’s proposed generic product before patent expiry would infringe the asserted claims.

The case therefore involved two separate questions:

1. Whether Mylan’s proposed aripiprazole product would infringe the asserted patent claims.
2. Whether Mylan could establish that the claims were invalid or otherwise unenforceable.

The filing of the lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and any court order modifying the stay.

What patents protected Abilify at the time?

Abilify was protected by a layered patent estate. The original aripiprazole compound patent had already been litigated extensively in earlier cases. Later patents covered pharmaceutical compositions, formulations and related product characteristics.

Original compound patent

U.S. Patent No. 5,006,528 covered aripiprazole and related compounds. It expired in 2015 after patent-term adjustment. The expiration of that patent opened the market to generic aripiprazole, subject to any later-expiring patents and regulatory exclusivity.

The Federal Circuit previously upheld the validity and enforceability of the ’528 patent against generic challengers in Otsuka Pharmaceutical Co. v. Sandoz, Inc. The decision addressed obviousness and confirmed the commercial significance of the original compound patent estate. [1]

Later formulation and composition patents

U.S. Patent No. 8,017,615 was among the later patents associated with Abilify. Its claims were directed to aripiprazole pharmaceutical compositions rather than the basic chemical identity of aripiprazole itself.

Later patents could delay approval or create litigation exposure even after expiration of the ’528 compound patent. Their commercial effect depended on claim scope, Orange Book listing status, product-specific applicability and the generic applicant’s Paragraph IV position.

Patent category	Commercial purpose	Risk to generic applicant
Compound patent	Protects aripiprazole molecule	Broadest early market barrier
Composition patent	Protects defined pharmaceutical composition	Requires product-specific noninfringement or invalidity position
Formulation patent	Protects dosage-form or excipient arrangement	Can affect tablet design and launch timing
Method-of-use patent	Protects approved treatment method	May require a section viii carve-out
Process patent	Protects manufacturing method	Usually less direct if the ANDA product uses a noninfringing process

Did Otsuka win or lose the case?

Neither party received a reported merits victory in this action. The case was resolved without a published claim-construction decision, trial verdict or Federal Circuit merits opinion.

That distinction matters. A dismissal or settlement does not establish that:

• Otsuka’s asserted claims were valid;
• Mylan’s proposed product infringed;
• Mylan’s Paragraph IV arguments were legally correct; or
• the asserted patent would have survived a full invalidity challenge.

The practical result was a confidential or nonpublic commercial resolution rather than a judicial determination of patent validity or infringement.

Was there a Paragraph IV challenge?

Yes. The litigation arose from Mylan’s Paragraph IV certification against an Otsuka-listed patent. A Paragraph IV certification states that the applicant believes the listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

A Paragraph IV filing gives the brand company a basis to sue before commercial launch. If the brand company files within 45 days after receiving the certification notice, FDA approval is generally stayed for 30 months unless the court resolves the case earlier or another statutory event ends the stay. [2]

The Paragraph IV challenge created several possible outcomes:

• Otsuka could win a judgment delaying Mylan’s approval until patent expiry.
• Mylan could prevail on invalidity or noninfringement.
• The parties could settle on a negotiated launch date.
• Mylan could redesign its product or pursue a different certification.
• The case could end before the court reached the merits.

The public disposition of this case supports the settlement or negotiated-resolution scenario, not a litigated determination on the patent claims.

What was the litigation timeline?

Date or period	Event
2014	Mylan filed an ANDA-related Paragraph IV challenge involving aripiprazole and Otsuka’s listed patent estate.
2014	Otsuka filed Case No. 1:14-cv-04508 in the District of New Jersey.
2014-2015	The parties proceeded under Hatch-Waxman litigation procedures, including pleadings, discovery and patent-case scheduling.
2015 or later	The action was resolved without a reported merits opinion.
After resolution	Generic aripiprazole products entered the U.S. market after the relevant compound-patent barrier ended and later patent issues were addressed.

The docket should be distinguished from Otsuka’s other Abilify cases involving different defendants, ANDAs, patents and settlement terms. A settlement in one Abilify action does not automatically establish the launch date or rights of every other generic applicant.

What was the Orange Book status of Abilify?

The FDA Orange Book listed patents for Abilify products. The relevant listing analysis required matching:

• the NDA product;
• dosage form;
• strength;
• listed patent;
• patent-use code, if applicable;
• expiration date; and
• the generic applicant’s certification.

The ’528 patent was the principal compound patent and expired in 2015. Later-listed Otsuka patents could extend litigation risk beyond that date, but they did not necessarily block every generic product in every strength.

Orange Book listing alone does not prove that a patent is valid or infringed. It gives the patent procedural significance under the Hatch-Waxman framework.

Orange Book implications for generic entry

A generic applicant could pursue several strategies:

1. File a Paragraph III certification and wait for patent expiry.
2. File a Paragraph IV certification and challenge the listed patent.
3. Submit a section viii statement carving out a patented method of use.
4. Design a formulation that avoids asserted composition claims.
5. Launch after settlement or after a favorable court ruling.

For Abilify tablets, the central commercial issue was whether later composition or formulation patents could delay approval after the basic aripiprazole compound patent expired.

Did the case involve a formulation patent?

Yes. The dispute was associated with Otsuka’s later composition and formulation protection for aripiprazole tablets. These patents generally have narrower claim scope than a compound patent because they depend on defined pharmaceutical ingredients, physical properties, dosage forms or manufacturing parameters.

Formulation patents can be commercially important even when they are vulnerable to design-around strategies. A generic applicant may avoid infringement by changing:

• excipient identity;
• excipient concentration;
• tablet composition;
• granulation conditions;
• particle-size distribution;
• manufacturing sequence; or
• other claimed product characteristics.

The strength of a formulation patent depends on whether the asserted claims capture the ANDA product as filed. Because the ANDA is the relevant product specification for infringement analysis, later commercial manufacturing changes can create separate regulatory and litigation issues.

Did the case involve method-of-use patents?

The Abilify patent estate included patents and regulatory listings that could raise method-of-use issues. Method-of-use patents are materially different from composition patents.

A generic applicant may attempt a section viii carve-out when the patented indication can be removed from the proposed labeling while leaving unpatented uses available. That strategy is unavailable where the patent claims the product itself or where the proposed label still encourages the patented use.

The public record for Case No. 1:14-cv-04508 does not establish a reported merits ruling on a method-of-use claim. The principal litigation risk in this action was the listed patent challenge connected to generic aripiprazole tablets.

Were there biosimilar issues?

No. This was not a biosimilar case.

Abilify is a small-molecule drug, and Mylan’s product proceeded through the ANDA pathway rather than the biologics license application and abbreviated biologics license application pathways. The relevant competitors were generic-drug applicants, not biosimilar sponsors.

The distinction affects:

• approval standards;
• interchangeability rules;
• exclusivity periods;
• patent-certification procedures;
• manufacturing disclosure; and
• launch economics.

What was the commercial effect of the litigation?

The litigation protected the timing of generic aripiprazole entry rather than creating a permanent monopoly. Once the original compound patent expired and regulatory barriers were addressed, multiple generic suppliers could compete.

The likely commercial consequences were:

• delayed generic entry during the statutory stay and litigation period;
• preservation of Abilify revenue during the protected period;
• reduced price after multiple generic launches;
• limited value for narrow formulation claims after the compound patent expired; and
• increased importance of manufacturing cost and supply reliability.

Generic entry into a mature oral solid-dose market usually causes rapid price erosion when several approved suppliers are available. The scale of erosion depends on the number of approved ANDAs, pharmacy substitution, payer policies, authorized generic strategy and supply constraints.

Publicly available information does not establish a case-specific settlement payment, royalty, launch date or volume commitment for the Otsuka-Mylan agreement. Those terms should not be inferred from the docket termination.

How strong was Otsuka’s patent position?

Otsuka’s patent position was strongest before expiration of the ’528 compound patent because that patent covered the active molecule broadly. After 2015, the estate became more dependent on narrower patents.

Factor	Assessment
Original compound protection	Strong historically; litigated and upheld in earlier Federal Circuit precedent
Later composition patents	Potentially meaningful but narrower
Formulation design-around risk	Material
Paragraph IV exposure	High enough to produce litigation
Biosimilar exposure	Not applicable
Manufacturing barrier	Product- and process-specific
Settlement leverage	Stronger before compound-patent expiry; weaker as generic competition expanded
Long-term exclusivity	Dependent on later patent claims and regulatory protections

The absence of a merits judgment in this case limits the value of the case as precedent. It does not weaken the earlier Federal Circuit ruling on the original compound patent, but it leaves the specific asserted later patent claims without a reported adjudication.

Which companies challenged Abilify patents?

Otsuka litigated Abilify-related patent disputes against multiple generic applicants, including Sandoz, Teva-related entities, Barr and Mylan. These cases involved different procedural postures and patents.

The most important precedent was Otsuka Pharmaceutical Co. v. Sandoz, Inc., in which the Federal Circuit affirmed the validity of the ’528 patent. Other cases, including Mylan’s action, addressed later patent rights and commercial-entry issues.

A competitor’s success or settlement in one case cannot be applied automatically to another applicant because:

• ANDA formulations differ;
• Paragraph IV certifications differ;
• asserted claims differ;
• patent expiration and patent-term adjustment may differ; and
• settlement terms are often confidential.

What generic launch risks remained after the case ended?

The principal launch risks were:

1. Patent risk. Later Otsuka patents could support separate infringement actions.
2. Regulatory risk. FDA approval could remain subject to the Hatch-Waxman stay or unresolved certification issues.
3. Labeling risk. A carve-out could be challenged if the proposed label still encouraged a patented use.
4. Supply risk. Generic launch economics depend on reliable active pharmaceutical ingredient and finished-dose supply.
5. Competition risk. Multiple approved suppliers could compress prices quickly.
6. Settlement restrictions. Any confidential agreement could limit or condition launch rights.

The case did not produce a public ruling eliminating all Otsuka patent risk. It resolved the dispute between Otsuka and Mylan.

What is the current litigation significance of Otsuka v. Mylan?

The case is commercially relevant as an example of post-compound-patent Hatch-Waxman litigation involving a branded small-molecule product. Its main lessons are:

• later formulation patents can remain relevant after compound-patent expiry;
• a Paragraph IV certification can trigger litigation even when the primary compound patent is near expiration;
• settlement, rather than trial, may determine the practical generic launch date; and
• a docket termination without a merits opinion provides limited precedent on validity and infringement.

The case should be analyzed alongside the Orange Book patent list, the FDA approval history for generic aripiprazole and Otsuka’s earlier Federal Circuit litigation.

Key Takeaways

• Otsuka sued Mylan in the District of New Jersey in Case No. 1:14-cv-04508 over generic aripiprazole tablets.
• The action was a Hatch-Waxman case triggered by a Paragraph IV certification.
• The dispute involved Otsuka’s later aripiprazole composition and formulation patent estate, including U.S. Patent No. 8,017,615.
• The original aripiprazole compound patent, U.S. Patent No. 5,006,528, expired in 2015.
• The case ended without a reported trial, claim-construction ruling or merits judgment.
• No public decision establishes whether Mylan’s proposed product infringed or whether the asserted patent claims were valid.
• This was a generic-drug case, not a biosimilar dispute.
• The commercial impact was primarily the timing of generic aripiprazole entry and the protection of Abilify revenue during the litigation period.

FAQs

What was Otsuka Pharmaceutical v. Mylan about?

It was a Hatch-Waxman patent lawsuit concerning Mylan’s proposed generic aripiprazole tablets and Otsuka’s Abilify-related patent rights.

Did Mylan win the Abilify patent lawsuit?

No reported merits judgment awarded Mylan a victory. The case ended without a published decision resolving infringement or validity.

When did the original Abilify patent expire?

U.S. Patent No. 5,006,528, the principal compound patent for aripiprazole, expired in 2015 after applicable patent-term adjustment.

Is Abilify a biologic subject to biosimilar competition?

No. Abilify is a small-molecule drug. Generic aripiprazole products use the ANDA pathway rather than the biosimilar pathway.

Can a formulation patent delay generic aripiprazole after compound-patent expiry?

Yes. A listed formulation or composition patent can create additional Hatch-Waxman litigation and delay approval or launch if the generic product is found to infringe and the patent is upheld.

References

1. Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).

2. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,017,615.

5. U.S. District Court for the District of New Jersey. (2014). Otsuka Pharmaceutical Co., Ltd. v. Mylan Inc., No. 1:14-cv-04508.